Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease.

ABSTRACT:

Background

Genetic variation of matrix metalloproteinase 9 (MMP-9) gene polymorphism has been suggested to modulate coronary heart diseases (CHD), yet the underlying mechanisms are not well understood.

Methods

We investigated the association of MMP9 rs3918242 single nucleotide polymorphism with inflammation and lipid-lowering efficacy after simvastatin treatment in Chinese patients with CHD. Fasting serum lipid profile and plasma inflammatory mediators were determined at baseline in 264 patients with CHD and 186 healthy control subjects, and after HMG-CoA reductase inhibitor simvastatin treatment (20 mg/day) for 12 weeks in CHD subjects.

Results

We found that plasma MMP-9, TNF-α and IL-10 levels were significantly elevated in patients with CHD compared to control subj

SUBMITTER: Xu Y 

PROVIDER: S-EPMC5385050 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature